Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419355 | 0.92 | SIGMAR1 (0.49) | GRM2SIGMAR1 | |
| SCHEMBL6414789 | 0.90 | GRM2 (0.51) | GRM2SIGMAR1 | |
| SCHEMBL6416588 | 0.89 | SIGMAR1 (0.47) | GRM2SIGMAR1FADS1 | |
| SCHEMBL6411665 | 0.88 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL6413115 | 0.86 | HTR1A (0.57) | GRM2SIGMAR1 | |
| SCHEMBL6416520 | 0.86 | P2RX7 (0.41) | GRM2SIGMAR1FADS1P2RX7 | |
| SCHEMBL6410904 | 0.86 | ATM (0.43) | GRM2SIGMAR1 | |
| SCHEMBL6415186 | 0.84 | GRM2 (0.50) | GRM2SIGMAR1 | |
| SCHEMBL6411816 | 0.84 | SIGMAR1 (0.52) | GRM2SIGMAR1 | |
| SCHEMBL6411733 | 0.84 | GRM2 (0.47) | GRM2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | GRM2 97/4885SIGMAR1 60/4885FADS1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.